Phase 2 Rheumatoid Arthritis Trial, Recruiting NCT06998628 Sponsor: Tanta University Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 2 Rheumatoid Arthritis Trial, Recruiting

NCT06998628
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have active rheumatoid arthritis that is not currently in remission, confirmed by a standard joint activity score (called DAS28) above 2.6.
  • People who are currently being treated with conventional disease-modifying antirheumatic drugs (a standard class of medication used for rheumatoid arthritis).
  • People of any gender.
  • People between 18 and 70 years of age.

Who may not be able to join:

  • People who have bleeding in the retina (back of the eye) or bleeding in the brain.
  • People who have reduced kidney or liver function.
  • People who have a known allergy or sensitivity to the medications being used in this trial.
  • Women who are pregnant or currently breastfeeding.
  • People who are being treated with biological or synthetic disease-modifying antirheumatic drugs (a more advanced class of rheumatoid arthritis medication, different from conventional types).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
2 June 2025
Est. completion
30 May 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

change in Disease Activity Score (DAS28)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov